Diabetic? Here's Why You Need a Glucagon Pen
Prescribing Information for Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors (Based on US Labels) | Radcliffe Cardiology
Xeris' glucagon injection Gvoke gains heat with HypoPen auto-injector launch | Fierce Pharma
Using the New Gvoke HypoPen: Glucagon Product Review
Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News
GVOKE (glucagon injection) Xeris Pharmaceuticals, Inc. These highlights do not include all the information needed to use GVOKE safely and effectively. See full prescribing information for GVOKE. GVOKE (glucagon injection), for subcutaneous
Preparing and Using a Glucagon Emergency Kit – Resus Review
FDA OKs Ready-To-Use Gvoke Glucagon By Xeris
Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News
789 Important Things to Know About Gvoke HypoPen® (glucagon injection) — JUICEBOX PODCAST
GlucaGen® HypoKit® Official Product Site
Glucagon
Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News
Glucagon
Fresenius Kabi Introduces Glucagon Emergency Medicine Kit to Treat Life-Threatening Episodes of Low Blood Sugar - Fresenius Kabi USA
Company name and structure
Harnessing Hypos: Glucagon As An Everyday Tool | Insulin Nation
Glucagon for hypoglycaemia treatment in type 1 diabetes - Ranjan - 2021 - Diabetes/Metabolism Research and Reviews - Wiley Online Library
Glucagon Options for People with Diabetes - Children with Diabetes
Harnessing Hypos: Glucagon As An Everyday Tool | Insulin Nation
Glucagon rescue - Wikipedia
Xeris raises $41M to develop diabetes injection pen for glucagon administration | Fierce Pharma
Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar
Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar
Xeris Doses First Patient in Phase 2 Study of Mini-dose Glucagon for mild-moderate hypoglycemia in T1D patients
